跳转至内容
Merck
CN

204903

抗补体5b-9 兔pAb

liquid, Calbiochem®

别名:

抗末端补体复合物,抗膜攻击复合物,抗MAC

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.43
UNSPSC Code:
12352203
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

抗补体5b-9 兔pAb, liquid, Calbiochem®

biological source

rabbit

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

form

liquid

contains

≤0.1% sodium azide as preservative

species reactivity

human, mouse

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
avoid repeated freeze/thaw cycles

dilution

(Frozen Sections
Immunofluorescence
Paraffin Sections (heat pre-treatment required)
Radial Immunodiffusion (use undiluted))

isotype

IgG

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

Application

冷冻切片(参见应用参考)

免疫荧光(参见注释)

石蜡切片(参见注释,需要加热预处理)

径向免疫扩散 (使用未稀释产品)

Disclaimer

毒性:标准处理(A)

General description

蛋白A纯化的兔多克隆抗体。识别C5b-C9 补体成分复合物。
识别补体成分复合物 Cb5-C9。
该抗补体5b-9兔pAb经验证可用于冷冻切片、免疫荧光、石蜡切片、径向免疫扩散以检测补体5b-9。

Immunogen

纯化的人 SC5b-9 复合物

Other Notes

Schafer, H., et al. 1986.J. Immunol.137, 1945.
通过免疫扩散,该抗体对纯化形式或存在于眼镜蛇毒因子激活的人血清中的 C5b-9 复合物具有单特异性。与未活化的正常人血清或血浆没有反应性。据报道还用于免疫荧光。该抗体适用于福尔马林固定的石蜡切片; 抗原修复需要使用柠檬酸盐缓冲液和高压锅蒸煮1 分钟。在单个系统中,应对抗体进行滴定以获得最佳结果。

Packaging

请参考特定浓度批号的标签。

Physical form

在PBS,pH 7.2中。

Preparation Note

初次解冻后,分装并冷冻保存(-20°C)。

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Xiao Han et al.
International journal of molecular sciences, 18(1) (2017-01-21)
The initiator of extrinsic coagulation, tissue factor (TF), and its non-coagulant isoform alternatively spliced TF (asTF) are closely associated with tumor development. In the tumor microenvironment, the role of TF-induced coagulation in tumor progression remains to be fully elucidated. Using
Maria Martin et al.
Kidney international reports, 9(7), 2227-2239 (2024-07-31)
Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)-mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing
Todor Tschongov et al.
Frontiers in immunology, 15, 1383123-1383123 (2024-05-27)
Most drugs that target the complement system are designed to inhibit the complement pathway at either the proximal or terminal levels. The use of a natural complement regulator such as factor H (FH) could provide a superior treatment option by
Ting-Ting Gao et al.
International journal of ophthalmology, 8(4), 675-680 (2015-08-27)
To investigate the expression of complement factors in the posterior scleral fibroblasts of guinea pigs with negative lens-defocused myopia. Eighteen guinea pigs were assigned randomly to two groups: the negative lens-defocused group (NLD group, n=9) and the normal control without
Mohammed Alshareef et al.
International journal of molecular sciences, 24(12) (2023-06-28)
Germinal matrix hemorrhage (GMH) is a pathology that occurs in infancy, with often devastating long-term consequences. Posthemorrhagic hydrocephalus (PHH) can develop acutely, while periventricular leukomalacia (PVL) is a chronic sequala. There are no pharmacological therapies to treat PHH and PVL.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持